BioSpace News Archive

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 39th Annual J.P. Morgan Healthcare Conference via webcast. BD’s CEO and president is scheduled to present on Tuesday, January 12, 2021 at 7:30 a.m. Eastern Time.

Hyundai Bioscience (KOSDAQ symbol: 048410) announced on the 23rd, December 2020, that CNPharm, its major shareholding bio tech company, has succeeded in developing ‘Poly-COV01,’ an injection drug for the potential treatment of patients with severe cases of COVID-19

Healthcare Services Acquisition Corporation (the “Company”) today announced the pricing of its upsized initial public offering of 28,800,000 units at a price of $10.00 per unit.

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced that Pfizer Inc. has selected antibodies directed at a previously-selected target under the companies’ cancer immunotherapy research collaboration and license agreement.

The new MRI on wheels is cleared for brain imaging and can be brought directly to the patient, making care easier and more convenient for a wide variety of patients, including children, emergency patients and patients with coronavirus.

Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has closed the transaction with CAIAC Fund Management AG for the Companys remaining holdings in its Polish subsidiary, Helix Immuno-Oncology S.A.

Zenith Capital Corp. (“Zenith” or the “Company”) announces that, at its annual and special meeting of shareholders held earlier today, Zenith shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated November 9, 2020 (the Information Circular), which is available on SEDAR at www.sedar.com, and on the Zenith website at www.zenithepigenetics.com . A webcast archive of the executive pres

908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the closing of its upsized initial public offering of shares of its common stock, with 7,475,000 shares offered and sold by the Company at a public offering price of $20.00 per share, which includes the full exercise of the underwriters’ option to purchase an additional 975,000 shares of comm

MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that the Company has agreed to settle an amount of $65,000 owing to a professional advisor, subject to all relevant consents and approvals, by issuing 500,000 common shares to the vendor, at a price of $0.13 per share. Regulatory and other consents will include acceptance from the TSX Venture Exchange. About MedX MedX, headquartered in Mississauga, Ontar

Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that the U.S. Food and Drug Administration (FDA) has notified Neurocrine Biosciences (Nasdaq: NBIX) that it has placed a clinical hold on the RESTORE-1 clinical trial of NBIb-1817 (VY-AADC). As previously announced, trial sites participating in RESTORE-1 had not been screening, enrolling or dosing patients as a result of the COVID-19 pandemic and more recently, as a result of the indep